Disclosure of Boxed Warnings to Research Participants
Medical experimentation on human subjects may involve drugs already approved for marketing by the US Food and Drug Administration (FDA). About 35% of FDA-approved drugs carry a boxed warning in the manufacturer's full prescribing information, 1 usually because of a potential toxic effect "so serious in proportion to the potential benefit from the drug (eg, a fatal, lifethreatening, or permanently disabling adverse reaction) that it is essential that it be considered in assessing the risks and benefits of using the drug." 2(p11) The consent form both documents and facilitates the process for negotiation of consent between the study participant and investigator. Here, we assess adequacy of disclosure of boxed warning risks to study participants on consent forms. Results | We identified 44 boxed warning risks applicable to 57 protocols (1.2% of all human research protocols) that involved 17 study drugs (Table) . Of the 57 protocols, 43 (75%) involved participants with life-threatening diseases.
Of the corresponding 57 consent forms, 36 (63%) did not disclose boxed warning risks. All sponsored research protocols in this study were for multicenter studies. The rate of nondisclosure of 1 or more boxed warning risks in a consent form was 17 of 21 (81%) for nonsponsored research, 9 of 16 (56%) for industry-sponsored research, and 10 of 20 (50%) for government agency-sponsored research. The nondisclosure rate for nonsponsored research was significantly higher than for government agency-sponsored research (P < .05); differences among other pairs were not statistically significant (P > .16).
Discussion | We found that for protocols involving drugs with boxed warnings, 63% of consent forms did not disclose 1 or more boxed warning risks. The higher nondisclosure rate of boxed warnings in nonsponsored research compared with government agency-sponsored research may reflect procedural variability, as sponsored research projects typically involve multiple levels of internal and external review. Investigators and sponsors have access to more information about risk of harm than do patients and study participants. Sponsors and investigators have inherent conflicts of interest, as clinical trials may generate income or enhance reputation. Moreover, some investigators are clinicians providing routine medical care to study participants who are also their patients. Adequacy of informed consent is of particular concern with vulnerable, gravely ill patients who participate in clinical trials.
